Washington State Elimination Strategy Slashes Hepatitis C Treatment Costs While Expanding Healthcare Access

UW study shows Washington's 2030 hepatitis C elimination goal has cut per-patient costs by 45% while significantly increasing access to life-saving testing.

By: AXL Media

Published: Apr 24, 2026, 4:04 AM EDT

Source: Information for this report was sourced from University of Washington

The Economic Evolution of a Public Health Directive

When former Governor Jay Inslee signed a first-in-the-nation directive in 2018 to eliminate hepatitis C, the primary challenge was bridging the gap between highly effective cures and the marginalized communities disproportionately affected by the virus. A new longitudinal study led by Ashley Tabah at the University of Washington has now quantified the economic and clinical impact of this initiative. By analyzing claims data for approximately 70% of the state’s population, researchers demonstrated that early investment in screening and discounted drug purchasing models did not just expand access to life-saving care, but began to stabilize the long-term financial burden on the state’s healthcare system.

A Surge in Screening and Diagnostic Accuracy

The implementation of the elimination plan triggered a massive increase in diagnostic activity across Washington. Data shows that the median number of HCV tests rose from roughly 28,000 per month in 2017 to a peak of nearly 100,000 by mid-2020. This surge aligned with updated national guidelines suggesting that all adults receive at least one lifetime screening. While this aggressive testing initially caused a spike in reported cases, the volume eventually began a significant downward trend as the backlog of untreated patients was cleared, illustrating the program's success in identifying and neutralizing the viral reservoir within the population.

Shifting the Financial Burden Toward Prevention

The financial trajectory of the program followed a classic "spend to save" model. Total monthly costs for hepatitis C care spiked from $45.6 million in 2017 to over $70 million in 2019 as thousands of newly diagnosed patients entered treatment. However, by 2021, these monthly costs had receded to $56.8 million. The most striking finding was the 45% reduction in costs per patient, which researchers attribute to catching infections in otherwise healthy, asymptomatic individuals. Treating patients before the onset of advanced liver disease or cirrhosis significantly reduces the complexity and duration of care, making the initiative a model for high-value public health investment.